摘要
大多数非小细胞肺癌肺癌患者确诊时已处于复发或转移的晚期阶段,化疗成为其主要的治疗方法,但其疗效迅速进入了平台期,但在过去的一年中,所公布的一系列靶向药物治疗非小细胞肺癌临床试验结果鼓舞人心,分子靶向治疗也给这部分人群带来了希望。
Most patients with non-small cell lung cancer are diagnosed at advanced stage of recurrence or metastasis,chemotherapy becomes the main treatment method and the efficacy enters into plateau stage soon,however,in the past year,with the publication of encouraging results of a series of clinical trials of targeted therapy of non-small cell lung cancer,molecular targeted therapy brings hope to this population.
出处
《中国处方药》
2010年第4期42-44,5+72,共3页
Journal of China Prescription Drug